Loading...
•
Sep 30, 2021
Ultragenyx Q3 2021 Earnings Report
Reported third quarter results with total revenue of $81.6 million, including Crysvita revenue of $50.3 million.
Key Takeaways
Ultragenyx reported third quarter 2021 financial results, with total revenue of $81.6 million. Crysvita revenue in Ultragenyx territories increased 35% compared to the third quarter of 2020. The company is preparing to initiate four additional studies across multiple modalities.
Crysvita revenue in Ultragenyx territories increased 35% versus the third quarter 2020.
Dojolvi revenue grew 176% versus the third quarter of 2020.
The U.S. FDA removed the clinical hold, allowing GeneTx to begin dosing naïve pediatric patients in the Phase 1/2 study of GTX-102 in patients with Angelman syndrome.
Multiple patients with Wilson disease have been successfully screened and are enrolled in the baseline monitoring period prior to dosing in the seamless Phase 1/2/3 study.
Revenue by Segment
Forward Guidance
The company expects 2021 Crysvita revenue to be towards the upper end of the guidance range of $180 million to $190 million. Total operating expenses are expected to increase modestly.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...